Menu
Your Cart

Apostle MiniMax DNA Methyl Bisulfite Conversion Module, 24 rxn

Apostle MiniMax DNA Methyl Bisulfite Conversion Module, 24 rxn
Secured Shopping
Best security features
Apostle MiniMax DNA Methyl Bisulfite Conversion Module, 24 rxn

Introduction

Apostle MiniMax Methyl Library Preparation Module is a double-strand DNA methylation sequencing library preparation kit developed for MGI & Illumina sequencing platforms. It supports multiple options for adapters selection, including Vendor N Methyl Adapter (SI) Module (for MGI), Vendor N Methyl Adapter (MDI) Module (for MGI) and Apostle MiniMax Methyl Stubby Adapter (UDI) Module (with 10 nt Index), etc. This kit can be used to prepare whole-genome methylation sequencing library. When combined with Apostle MiniMax's liquid-phase hybridization capture series products, it enables targeted enrichment of methylation sequencing library.

 

Apostle MiniMax DNA Methyl Bisulfite Conversion Module is a methylation conversion reagent developed for DNA samples based on the principle of bisulfite conversion. The conversion module, based on a magnetic bead purification protocol, efficiently converts unmethylated cytosine to uracil within 2 hr, leaving methylated cytosine unchanged, and it can be compatible with automated workstations. It can be seamlessly integrated with Apostle's double-strand methylation library preparation scheme and single-strand methylation library preparation scheme, allowing flexible selection among various types of starting samples.

 

Information

Cat #

NA001311

Capacity

24 rxn

Performance

Check information page

Protocol

Download


Related reagents

Apostle MiniMax Methyl Library Preparation Module

24 rxn96 rxn

Apostle MiniMax DNA Methyl Bisulfite Conversion Module

24 rxn96 rxn

Apostle MiniMax Universal Stubby Adapter (UDI) Module Set E1

24 rxn96 rxn

Apostle MiniMax Methyl Stubby Adapter (UDI) Module Set B1 (with 10nt Index)

24 rxn96 rxn


$140.00
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.